The
coronavirus-pandemic is reshaping the biotech industry: Investors are piling in
to small, often unproven companies in hopes they can produce a vaccine in the
coming months. Those companies in turn, are spending big to expand production
facilities for vaccines that aren't yet fully tested, nor certified. It's a
gamble for both investor and company and it reflects the urgency for a vaccine
as well as the potential to make money.
What's
beyond doubt is that thanks to hi-tech methods used by the likes of CureVac,
research is moving faster than ever before. It used to take 10 to 15 years to
get a vaccine to market. Now some companies have reached the clinical trial
phase in a matter of months. Trusted institutions are expecting a breakthrough
as early as next year. No other product in the world has a larger potential
market. Many nations have already placed orders for hundreds of millions of
doses. CureVac plans to produce a billion a year, if its vaccine comes to
fruition. The question is whose will hit the market first.
Sem comentários:
Enviar um comentário